INTRODUCTION
Non-influenza respiratory viruses including respiratory syncytial virus (RSV), coronavirus, parainfluenza viruses (PIV), human metapneumovirus (hMPV), rhinovirus, and adenovirus cause severe disease in infants and the immunocompromised and are increasingly recognized as a common cause of severe acute respiratory illness among non-immunocompromised hospitalized adults [1, 2] . There are currently very few therapeutic options available for non-influenza respiratory virus infections and management is largely supportive. This review examines the currently used antiviral agents for severe non-influenza respiratory virus infections and promising antiviral agent currently in development. Table 1 lists the range of clinically important non-influenza respiratory viruses and summarizes antiviral agents in development.
BROAD-SPECTRUM ANTIVIRAL AGENTS
The oral antiprotozoal drug nitazoxanide has invitro antiviral activity against a range of respiratory viruses including influenza, RSV, and Middle East respiratory syndrome-coronavirus (MERS-CoV) [3, 4] and also against nonrespiratory viruses including hepatitis C, dengue virus, rotavirus, and norovirus. Nitazoxanide is a small molecule drug that targets host-regulated processes involved in viral replication. It has been investigated as an oral treatment for a several viral infections, including influenza, viral gastroenteritis, and chronic hepatitis C [3] . A large phase 2b/3 placebo-controlled trial of nitazoxanide treatment in adolescents and adults with influenzalike illness in primary care showed a reduction in the duration of symptoms in adults with influenza and also in those with non-influenza respiratory virus infection [5] .
Favipiravir (T-705) is an oral agent that inhibits the RNA-dependent RNA polymerase of wide range of RNA viruses including influenza, RSV, and rhinoviruses as well as many nonrespiratory RNA viruses [6] and was used as an experimental treatment for Ebola virus infection during the recent epidemic [7] . Clinical trials of favipiravir have been conducted in patients with uncomplicated influenza and it is approved for the treatment of influenza in Japan [8] .
RESPIRATORY SYNCYTIAL VIRUS
Ribavirin is a nucleoside analogue which interferes with RNA metabolism required for viral replication and has a broad spectrum of activity against many RNA and DNA viruses [9] . It is mainly used in the aerosolized form for RSV infection, but oral and intravenous formulations have also been used. Ribavirin has been used in infants with severe RSVinduced bronchiolitis, although trials have not shown consistent benefits and there are concerns over toxicity in this group [10] . In severely immunocompromised patients (principally hematopoietic stem cell transplant recipients), aerosolized ribavirin treatment is used to prevent RSV upper respiratory tract infection (URTI) progressing to a lower respiratory tract infection (LRTI) and to reduce mortality in RSV lower respiratory tract infection. Observational studies suggest that ribavirin reduces the risk of progression from URTI to LRTI and mortality, especially when commenced early in infection [11] [12] [13] ; however, definitive proof of efficacy from high-quality randomized controlled trials is lacking. The use of ribavirin is further limited by its toxicity and difficulties in safe administration of
KEY POINTS
Current antiviral treatment options for severe noninfluenza respiratory virus infection are extremely limited.
Ribavirin is used in severe RSV infection in young children and in severely immunocompromised adults, its but use is limited by toxicity and the evidence base for its efficacy is poor.
GS-5806 and ALS-8176 appear to reduce clinical severity of RSV infection in human challenge studies and are promising candidate antivirals undergoing latestage clinical trials.
Convalescent plasma and mAbs may be future therapeutic options for MERS-CoV infection.
Broad-spectrum antivirals, such as nitazoxanide and favipiravir, show promise in early studies across a range of respiratory viruses. the aerosolized form. Ribavirin is teratogenic and occupational exposure of staff can occur, and its use has also been associated with respiratory deterioration. The oral and intravenous formulations are also associated with hematological toxicity and are contraindicated in renal impairment. There have been two recent landmark human challenge studies of small molecule anti-RSV agents. GS-5806 (presatovir) is an F-protein (fusion) inhibitor that inhibits RSV entry into cells by blocking viral-envelope fusion with the host-cell membrane. GS-5806 reduced RSV viral load by around four-logs and reduced the severity of clinical symptoms compared with placebo in healthy adults infected with RSV in a human challenge study. Adverse events associated with GS-5806 included leukopenia and raised levels of alanine aminotransferase although these events were generally mild and the drug was well tolerated [14 & ]. ALS-8176 (lumicitabine) is a nucleoside analogue and inhibits the L-protein, the RNA-dependent RNA-polymerase of RSV. It inhibits RSV replication within cells already infected and protects uninfected cells from infection. ALS-8176 was associated with a reduction in viral load to undetectable levels and reduced severity of clinical symptoms compared with placebo in an RSV human challenge study. Elevated levels of alanine aminotransferase were the most common adverse event and the drug was well tolerated [15 & ]. Results of a completed phase 2b randomized controlled trial of GS-5806 in hospitalized adults with RSV infection are awaited and a phase 2b trial in hematopoietic stem cell transplant recipients is underway [16] . A phase 2a trial of ALS 8176 in hospitalized adults with RSV is currently underway [17] as is a trial in hospitalized infants [18] . It should be noted that a key limitation of the human challenge treatment model is that treatment is initiated very soon after the start of experimental infection and so the effects of prompt treatment may not be reproduced in clinical practice as patients hospitalized with respiratory virus infection generally present several days after symptom onset [1] .
ALN-RSV01 (asvasiran) is a small interfering RNA (siRNA) targeted against the mRNA of the RSV nucleocapsid. A human challenge study of intranasal ALN-RSV01 demonstrated that it prevented RSV infection and at higher doses had a treatment effect. This trial established proof-of-concept for RNA interference as a therapeutic option for viral infection and warranting further study [19 & ]. ALN-RSV01 has subsequently been shown to reduce the risk of bronchiolitis obilterans syndrome after RSV infection in lung transplant recipients [20, 21] .
ALX-0171 is a trivalent inhaled 'nanobody' that binds to a conserved epitope of the RSV F-protein with high RSV neutralizing potency and decreased capability to select escape mutants [22] . Results of clinical trials in hospitalized infants and children are awaited [23, 24] . Another fusion inhibitor AK0529 has completed phase I trials and is undergoing a phase 2 trial in hospitalized infants [25] . Other anti-RSV agents, such as MEDI8897, a recombinant human RSV monoclonal antibody (mAb) with a modified Fc region leading to a prolonged half-life, have undergone early phase trials but are directed at prevention rather than treatment [26] . Another mAb, motavizumab, evaluated as treatment in a clinical trial, failed to show any reduction in viral load, severity of illness, or duration of hospitalization in infants hospitalized with RSV infection [27] . Compassionate use of high-titer anti-RSV intravenous immunoglobulin in high-mortality-risk hematopoietic stem cell transplant recipients with RSV infection appears well tolerated and increased serum neutralizing antibody titers to RSV in one retrospective study; however, definitive evidence of efficacy from placebo-controlled studies is lacking [28] .
MIDDLE EAST RESPIRATORY SYNDROME-CORONAVIRUS
Despite a promising preclinical study, treatment of MERS-CoV with ribavirin and interferon in observational studies has not been associated with reduced mortality [29, 30] . A meta-analysis of patients with severe acute respiratory syndrome coronavirus (SARS-CoV) and influenza has suggested that treatment with blood products from convalescent patients may be associated with decreased mortality and so hyperimmune and convalescent plasma from patients who survived MERS-CoV infection could be a potential future therapy [31] . However, collection of sufficient quantity of such blood products may be an insurmountable barrier to developing a treatment [32] . Several neutralizing mAbs have been developed which bind to the viral surface spike (S) protein of MERS-CoV, therefore preventing viral entry and membrane fusion. These mAbs have demonstrated potent inhibition of the virus in vitro and protection from lethal challange in animal models and are now in the stage of being taken forward into clinical stuidies in humans [33, 34] .
PARAINFLUENZA VIRUS AND HUMAN METAPNEUMOVIRUS
Ribavirin has been used in heavily immunocompromised patients with parainfluenza and hMPV infections, but the evidence base for efficacy is weak and as detailed above its uses is limited by difficulties in www.co-infectiousdiseases.comadministering the aerosolized form and by its toxicity. DAS181 (fludase) is an inhaled sialidase that cleaves sialic acid from host respiratory epithelial cells, which is required for both influenza and PIV to bind and therefore has antiviral activity against these viruses. DAS181 has undergone phase I trials and was found to be safe and generally well tolerated, and is currently being evaluated for the treatment of parainfluenza infections in adults in a phase 2 placebo controlled trial in the USA [35] . DAS181 may also have activity against hMPV [36] . According to pipeline reports, AL-8176 (Lumicitabine) has been found to have activity against other paramyxoviruses including PIV and hMPV, and studies are undeway but are currenly at the preclincal stage (http://www.aliosbiopharma.com/pipeline/overview/). An agent with broad-spectrum antiviral activity agaist these viruses could represent a major advancement in the treatment of respiratory virus infections in high-risk populations.
PICORNAVIRUSES
Pleconaril is an oral viral capsid inhibitor with broad antiviral activity against picornaviruses, which includes rhinoviruses and enteroviruses. It was effective in reducing the duration and severity of common colds in adults caused by picornaviruses in two randomized controlled trials [37] . However, concerns over the potential for the emergence of antiviral resistance, drug interactions with the oral contraceptive pill, and study populations being limited to healthy participants meant that pleconaril was not approved for clinical use [38] and it is not being devlopeed further. BTA798 (Vapendavir) is another small molecule capsid-binding agent which was recently evaluated in a phase 2b trial in adults patients with rhinovirus-induced asthma exacerbations but failed to demonstrate efficacy [39] .
The ex-vivo bronchial epithelium of asthmatic patients is associated with a defective innate immune response to rhinovirus infection which is restored by adding exogenous beta interferon (INF-B) [40] . A placebo-controlled trial of inhaled IFN-b in asthmatic patients with cold symptoms did not meet its primary outcome measure but suggested that inhaled IFN-b was effective at attenuating exacerbations in a subset of patients with severe asthma [41] . A subsequent multicenter phase II trial of inhaled IFN-b in severe patients with asthma administered at the onset of cold symptoms was recently ceased due to a very low number of reported exacerbations occurring during the trial, meaning that the primary outcome measure could not be reached [42] 
ADENOVIRUS
Adenovirus can occasionally cause severe acute respiratory illness in immunocompetent adults [43] but more commonly causes severe infection in heavily immunocompromised patients. Cidofovir is an intravenous nucleoside analogue that inhibits viral DNA polymerase and is used in immunocompromised patients with disseminated and progressive adenovirus infection or preemptively in patients with persistent replication [44, 45] . Its use is limited by toxicity, most notably nephrotoxicity. Brincidofovir is an oral lipid conjugate of cidofovir that increases its cellular uptake and is potentially more potent and less toxic. It has been used experimentally in a small number of immunocompromised patients with severe adenovirus disease and a larger number with asymptomatic adenovirus infection as a preemptive treatment, but larger-scale randomized controlled trials are needed [46, 47] .
CONCLUSION
Non-influenza respiratory viruses are responsible for a large burden of severe disease. Respiratory virus testing in hospitalized patients with acute respiratory illness is currently underutilized, but a routine testing strategy with rapid molecular diagnostic platforms has the potential to detect respiratory virus infection at presentation and direct the use of novel antiviral agents when available [48 & ,49] . Current therapeutic options for severe disease caused by non-influenza respiratory viruses are extremely limited. Aerosolized ribavirin is sometimes used in severe RSV infection in infants and in heavily immunocompromised adults, but its use is limited by toxicity and by a lack of high-quality evidence for its efficacy. Multiple novel candidate antivirals are undergoing clinical trials including some with some broad antiviral activity, such as nitazoxanide and favipiravir. Several promising small molecule drugs active against RSV are in the late stages of development. Convalescent plasma and monoclonal antibodies may be future treatments for MERS-CoV infection.
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